Cell and Gene Therapies: Skills Provision
(Limited Text - Ministerial Extracts only)
Read Full debate
The Minister for Health and Secondary Care (Will Quince)
I start by congratulating the hon. Member for Blaydon (Liz Twist) on securing this important debate. Before I get into the substance of the debate, I wanted specifically to thank her for raising the issue of SMA and Freddie’s case. To answer that specific point directly, because it is an issue that I am alive to—I alluded to it in the previous debate just a few moments ago—my understanding is that the University of Sheffield is currently undertaking work that specifically relates to SMA and the gathering of evidence to present to the National Screening Committee. I hope that will be welcome news, and as there are developments, I will certainly keep the hon. Lady updated.
The hon. Lady is absolutely right when she says that a highly skilled workforce is critical to developing these therapies and making sure that UK patients benefit. The right training and education will also provide those joining this hugely important industry with a rewarding career that they can be proud of. The UK is a leader in cell and gene therapies: nearly a quarter of Europe’s cell and gene therapy developers are headquartered in this country. The number of cell and gene therapy clinical trials conducted in the United Kingdom also continues to increase, from 28 phase 3 trials in 2020 to 44 in 2022.
As the hon. Lady mentioned, the number of cell and gene therapies coming to market is set to increase substantially, with over 1,500 clinical trials ongoing worldwide. Although the Government are funding many skills initiatives to prepare for that expansion, collaborations with industry, charities, the healthcare sector and—crucially—UK academia are also vital. The cell and gene therapy catapult, which is part funded through Innovate UK, is a key part of that collaborative approach, which provides practical training and identifies the skills that are needed across the sector.
The advanced therapies apprenticeship community, which was set up by the cell and gene therapy catapult with £1.5 million from the industrial challenge fund, is the first apprenticeship programme designed to train individuals in developing, manufacturing and—of course —delivering innovative advanced therapies at scale. That award-winning programme has supported over 300 apprentices, employed by 56 companies. In addition, the catapult has set up new state-of-the-art skills and training laboratories in Stevenage to sit at the heart of the world’s third largest cluster of advanced therapy companies.
In its latest cell and gene therapy skills demand survey, the catapult forecast a skills demand of 10,000 bioprocessing jobs by 2026, a growth of 151%. Earlier this year, at the May 2023 life sciences growth moment, we announced £54.5 million to boost UK medicines manufacturing, which included up to £38 million for a new biomanufacturing fund.
On 5 September—this goes specifically to the point about education and schools—we announced that £5.5 million of the life sciences growth funding would be used to establish a medicines manufacturing skills centre of excellence. The hon. Lady is absolutely right: we want to encourage more people, and young people in particular, to consider a career in this field. Upskilling talent from similar industries will also help to increase capacity. Backed by £4.7 million of Government funding, the advanced therapies skills training network is a national initiative to drive growth across the advanced therapies and vaccine manufacturing industry. It has supported over 3,285 learners to date, providing training and supporting uptake of new talent from different sectors while, vitally, also upskilling existing staff.
Clinical staff also need support to conduct research and learn new methods of delivering treatments. The advanced therapy treatment centres network is a world-first network operating within our NHS. Co-ordinated by the cell and gene therapy catapult, it addresses the challenges of bringing advanced therapies to patients. The ATTC has produced learning tools, including a knowledge-sharing platform, with more than 270 resources, which has had more than 28,000 hits worldwide.
Will Quince
As was raised multiple times in the previous debate, the National Institute for Health and Care Research supports the development of researchers, including through its £790 million investment in the biomedical research centres, of which 14 out of 20 currently conduct research into cell and gene therapies. Cell and gene therapies are also a strategic priority for the Medical Research Council, and it will be launching its updated advanced therapeutics strategy, which includes support for skills and training, later this year.
Between 2011 and 2022, the Medical Research Council funded over £30 million in advanced therapy-focused fellowships. It has also recently launched—I am afraid this is going to be difficult to say, as it is a bit of a mouthful—a cell and oligonucleotide therapy fellowship, in partnership with AstraZeneca, which aims to develop links with industry through secondments, training and mentoring. Innovation hubs for cell and gene therapies, which is an £18 million strategic initiative with co-funding from the MRC, the Biotechnology and Biological Sciences Research Council and LifeArc, has published a skills and training strategy that sets out how it will support skills in the sector.
We recognise that we need a skilled, innovative and responsive cell and gene therapy regulatory workforce—that is absolutely key—and I am pleased to say that the Medicines and Healthcare products Regulatory Agency is working with partners across the UK health ecosystem to create faster, risk-proportionate and predictable regulatory pathways, which are underpinned by the recruitment and training of highly qualified expert assessors. This will support innovation and create a compelling reason for companies to introduce new medical products in the UK.
In closing, let me again thank the hon. Member for Blaydon for securing this important debate. The UK already has the skills to deliver new therapies, but she is absolutely right to point out that it is vital that we continue to invest to ensure we have the right staff with the right skills to develop and harness the potential of these hugely exciting new therapies.
Question put and agreed to.